PMID- 22309489
OWN - NLM
STAT- MEDLINE
DCOM- 20121116
LR  - 20220331
IS  - 1365-2982 (Electronic)
IS  - 1350-1925 (Linking)
VI  - 24
IP  - 8
DP  - 2012 Aug
TI  - PPI therapy is equally effective in well-defined non-erosive reflux disease and 
      in reflux esophagitis: a meta-analysis.
PG  - 747-57, e350
LID - 10.1111/j.1365-2982.2012.01888.x [doi]
AB  - BACKGROUND:   Symptomatic response to proton pump inhibitor (PPI) therapy in 
      patients with non-erosive reflux disease (NERD) is often reported as lower than 
      in patients with erosive reflux disease (ERD). However, the definition of NERD 
      differs across clinical trials. This meta-analysis aims to estimate the rate of 
      symptom relief in response to PPI in NERD patients. METHODS: MEDLINE (1966-2010), 
      Cochrane Comprehensive Trial Register (1997-2010) and EMBASE (1985-2010) 
      databases were searched and manual searches from studies' references were 
      performed. Randomized clinical trials were selected that included patients with 
      heartburn, and analyzed the effect of short-term PPI treatment. The primary 
      outcome of selected studies was defined as complete or partial heartburn relief. 
      Two reviewers independently extracted data and assessed study quality of selected 
      articles. Random effects models and meta-regression were used to combine and 
      analyze results. KEY RESULTS: The pooled estimate of complete relief of heartburn 
      after 4 weeks of PPI therapy in patients with ERD was 0.72 (95% CI 0.69-0.74) (32 
      studies), vs 0.50 (0.43-0.57) (eight studies) in empirically treated patients, 
      0.49 (0.44-0.55) (12 studies) in patients defined as non-erosive by negative 
      endoscopy, and 0.73 (0.69-0.77) (two studies) in patients defined as non-erosive 
      by both negative endoscopy and a positive pH-test. CONCLUSIONS & INFERENCES: In 
      well-defined NERD patients, the estimated complete symptom response rate after 
      PPI therapy is comparable to the response rate in patients with ERD. The 
      previously reported low response rate in studies with patients classified as NERD 
      is likely the result of inclusion of patients with upper gastrointestinal 
      symptoms that do not have reflux disease.
CI  - (c) 2012 Blackwell Publishing Ltd.
FAU - Weijenborg, P W
AU  - Weijenborg PW
AD  - Department of Gastroenterology and Hepatology, Academic Medical Center, 
      Amsterdam, The Netherlands. p.w.weijenborg@amc.uva.nl
FAU - Cremonini, F
AU  - Cremonini F
FAU - Smout, A J P M
AU  - Smout AJ
FAU - Bredenoord, A J
AU  - Bredenoord AJ
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Research Support, Non-U.S. Gov't
DEP - 20120206
PL  - England
TA  - Neurogastroenterol Motil
JT  - Neurogastroenterology and motility
JID - 9432572
RN  - 0 (Proton Pump Inhibitors)
SB  - IM
CIN - Neurogastroenterol Motil. 2012 Sep;24(9):885-6; author reply 887. PMID: 22908863
MH  - Clinical Trials as Topic
MH  - Esophagitis, Peptic/*drug therapy
MH  - Gastroesophageal Reflux/*drug therapy
MH  - Humans
MH  - Proton Pump Inhibitors/*therapeutic use
MH  - Treatment Outcome
EDAT- 2012/02/09 06:00
MHDA- 2012/12/10 06:00
CRDT- 2012/02/08 06:00
PHST- 2012/02/08 06:00 [entrez]
PHST- 2012/02/09 06:00 [pubmed]
PHST- 2012/12/10 06:00 [medline]
AID - 10.1111/j.1365-2982.2012.01888.x [doi]
PST - ppublish
SO  - Neurogastroenterol Motil. 2012 Aug;24(8):747-57, e350. doi: 
      10.1111/j.1365-2982.2012.01888.x. Epub 2012 Feb 6.